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Abstract
Recent evidences demonstrated the importance of bone marrow derived Endothelial Progenitor 
Cells (EPC), in the contribution to postnatal physiological and pathological neovascularization, and in 
tumor growth and angiogenesis. These cells are recruited undifferentiated, in response to systemic 
or chemoattractive signals, such as Vascular Endothelial Growth Factor (VEGF), they lodge in the 
growing or lesioned tissue and differentiate into endothelial cells in response to local stimuli and 
cell-cell interactions. The extent and the significance of the EPCs contribution for the growing of most 
tumors, including those of the breast, are still not fully defined. We analyzed the peripheral blood 
of breast cancer patients and found that they have circulating EPCs. We also found an association 
between expression of AC133+Kdr+ and VEGF plasma levels in these patients. Strategies to impair 
the mobilization and incorporation of EPCs into breast tumors may contribute to halt the growth of 
these tumors. 
breast cancer development [11-14]. Since VEGF plasma levels 
are elevated in vascular trauma patients in comparison to VEGF 
levels in plasma of healthy donors, we sought to evaluate the VEGF 
plasma levels in breast cancer patients. We and others found that 
VEGF plasma levels in these patients correlates with the presence of 
AC133+KDR+ [11,12]. Given that our observations show an increase 
of circulating progenitor cells in the peripheral blood of breast cancer 
patients, we sought to evaluate the expression of AC133 and KDR 
in breast tumors. For this purpose RT-PCR of frozen breast tumors 
and matching normal tissue was performed. We found that 88.9% 
of breast tumors express AC133 and KDR. In contrast, only 25.0% 
of the normal adjacent tissue expressed these markers [12]. To our 
knowledge there is no report in the literature at present addressing 
AC133 and KDR expression in breast tissue. The tumor specimens 
that did not express the EPC’s markers were highly correlated with 
the size of the tumor (115.0 ± 4.1; p=0.0004), the tumor weight (516.0 
± 34.1; p=0.0088) and the age of the patient (69 ± 2.2; p=0.0159) [12]. 
These data suggest that breast tumors recruit EPCs in a very targeted 
and focal fashion and indicate that the tumor recruits EPCs during 
cancer progression and they are no longer needed when the tumor 
reaches a plateau of growth.
Taken together, these results show that breast cancer patients 
have elevated levels of VEGF and that these levels correlate with 
circulating AC133+KDR+ cells in these patients. Furthermore, the 
expression of these EPC’s markers in a panel of breast tumors but not 
in the respective adjacent normal tissue highlights the importance of 
these cells as targets for breast cancer therapy. It is expected that these 
cells could be used as biomarkers of early diagnosis and treatment of 
breast cancer.
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Introduction
Malignant transformation requires the generation of a fertile 
macro environment in which tumor cell proliferate, and under certain 
circumstances form a highly invasive and metastatic tissue [1,2].
The formation of new vessels within a tumor, angiogenesis, is 
dependent on proliferation and migration of endothelial cells [3]. Two 
possible sources of endothelial cells are (1) migration and co-option 
of pre-existing vascular walls endothelial cells or (2) recruitment of 
EPCs from the bone marrow [4].
Initial studies showed that EPCs could be identified by their 
expression pattern of specific cell-surface markers, which included 
Kinase Insert Domain Receptor (KDR) [4] and AC133 [5]. EPCs are 
tracked by the cell-surface molecule AC133, a five transmembrane-
spanning 120 kD glycoprotein [6,7]. It has been demonstrated 
previously that acute elevation of VEGF levels in vascular trauma 
patients is the primary factor inducing mobilization of EPCs [4] 
and it has been widely described that VEGF is up-regulated in most 
tumour types including those of the breast [8]. Gill and collaborators 
[4], have shown previously that late-outgrowth endothelial cells 
differentiating from the non-adherent population of plated Peripheral 
Blood Mononuclear Cells (PBMNCs) represent a population of BM-
derived anchorage-independent BM-derived EPCs characterized by 
high proliferative potential. These late-outgrowth colonies have been 
shown to be a characteristic of AC133+KDR+ cells [4]. There is a 
growing body of evidence showing that EPCs, AC133+KDR+ cells, 
might be implicated in the development of some tumors [9-11]. We 
analyzed the expression of EPC’s markers in PBMNCs from breast 
cancer patients by RT-PCR. Our results suggest that a population 
of cells expressing AC133 and KDR are mobilized to the peripheral 
circulation in breast cancer patients. We found that 16.7 % of breast 
cancer patients have circulating EPCs confirmed by the expression 
of AC133 and KDR markers [12]. These results are in agreement 
with several other authors who found that EPCs are recruited during 
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